Paul Thomas Buys Axogen, Inc. Shares
Paul Thomas acquired 18,867 shares of Axogen, Inc. on June 19, 2026.
Key Points
- Paul Thomas bought 18,867 shares of Axogen, Inc. on June 19, 2026, with the transaction being unplanned.
- Shares of AXGN traded near $44.95 on Wednesday with a market cap of about $2.39 billion and a forward P/E of 61.7.
- Insider buying included Wendell Amy McBride, Alan Levine, and others, while analysts maintained a positive outlook with buy ratings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Paul Thomas, an insider, acquired 18,867 shares of Axogen, Inc. (NasdaqCM: AXGN) on June 19, 2026. This transaction was not part of a pre-planned trading program. Although the value of the shares was not specified, such insider buying can sometimes signal confidence in the company's prospects.
Insider Buying and Selling at Axogen, Inc.
On June 19, 2026, several insiders, including Wendell Amy McBride, Alan Levine, and Kathy Johnson Weiler, also purchased shares of Axogen, Inc. Each bought 14,150 shares in unplanned transactions, reflecting a coordinated move among company insiders.
Axogen, Inc. Stock Down 13.2%
Shares of Axogen, Inc. traded near $44.95 on Wednesday. The company has a market capitalization of approximately $2.39 billion and a forward P/E ratio of 61.7, indicating expectations of future earnings growth. Axogen's stock has shown a 52-week range between $9.35 and $45.83. Its 50-day moving average is $40.43, while the 200-day moving average is $30.40. The company's financial health appears strong, with a current ratio of 7.10 and a quick ratio of 4.99.
$AXGN stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On April 29, 2026, several analysts maintained their buy ratings for Axogen, Inc. Canaccord Genuity, Citizens, and Wells Fargo all set price targets of $50. HC Wainwright & Co. also maintained a buy rating with the same target. The consensus among nine analysts is a target mean price of $50.78, reflecting a generally optimistic outlook.
About Axogen, Inc.
Axogen, Inc. is a medical device company based in Alachua, Florida. It focuses on developing and commercializing technologies for peripheral nerve regeneration and repair. The company provides products like the Avance Nerve Graft and Axoguard Nerve Connector, which are used in surgical repair and protection of peripheral nerves. Axogen serves hospitals and surgery centers worldwide, working with various types of surgeons to improve patient outcomes.
Bottom Line
Paul Thomas's recent acquisition of Axogen shares is part of a broader pattern of insider buying, suggesting confidence in the company's future. Axogen, which is engaged in peripheral nerve repair technologies, continues to attract analyst attention with maintained buy ratings and favorable price targets. As always, it's important to remember that insider transactions and analyst ratings are part of a larger picture and should be considered with other financial data and market conditions.
Get Axogen, Inc. alerts
New 13F filings, insider trades, and analyst moves on $AXGN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.